Resumo

FLORIANO-SANCHEZ, Esaú et al. Human papilloma-virus: Marker of response to radiotherapy/chemoradiotherapy in cervical cancer. Acta bioquím. clín. latinoam. [online]. 2010, vol.44, n.3, pp.337-346. ISSN 0325-2957.

Cervical cancer (CaCU) represents 6% of all malignancies in women. Molecular and epidemiological evidence relate the human papilloma virus (HPV) with the pathogenesis of the CaCU genotypes, the most frequent genotypes being 16 and 18 ( VPH-16 and -18). Radiotherapy (RT) and chemoradiotherapy (ChRT) are the two primary treatment modalities for CaCU, with variable rates of resistance or persistence of the disease. The aim of this work was to study for the first time, the tumorai response before, duríng and after RT and RT-QT and analyze HPV-16 and -18 viral load in a Mexican population with CaCU. Samples of tumor tissue were collected from patients with CaCU: before, duríng and after RT and ChRT. The absolute number of HPV-16 or -18 copies was determined, and the response related with viral load in both treatments was studíed by real-time PCR-based in fluorescence. The percentage of decrease ín HPV viral load for ChRT and RT was 100% and 62%, respectívely With ChRT, the response was better than with RTalone. HPV (-16 and -18) viral load ís suggested to be a potentíal índícator to evalúate CaCU response in both treatments.

Palavras-chave : Cervical cáncer; Human papilloma virus; Real-time polymerase chain reaction; Radiotherapy; Chemoradiotherapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )